Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


StemCells names president & COO

This article was originally published in Scrip

Executive Summary

Newark, California-based StemCells, a company developing novel cell-based therapeutics for disorders of the central nervous system, has named Ian Massey president and chief operating officer. In this new role, Dr Massey has direct responsibility for all aspects of the company's R&D, manufacturing, regulatory affairs and quality assurance activities. He will report to StemCells' CEO Martin McGlynn. Most recently, Dr Massey was the COO and president of US operations at Biotie Therapies, a publicly traded Finnish company focused on neurodegenerative and psychiatric disorders.


Related Content

StemCells Inc. To Wind Down Operations After Phase II Failure


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts